Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - brimonidine tartrate, quantity: 1.5 mg/ml - eye drops, solution - excipient ingredients: magnesium chloride hexahydrate; boric acid; sodium chlorite; sodium chloride; carmellose sodium; borax; sodium hydroxide; purified water; hydrochloric acid; potassium chloride; calcium chloride dihydrate - alphagan p 1.5 eye drops are effective in lowering elevated intraocular pressure in patients with chronic open angle glaucoma or ocular hypertension. alphagan p 1.5 eye drops can be used in the treatment of glaucoma as either monotherapy or in combination with topical beta blockers.

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - brimonidine tartrate 2 mg/ml;   - eye drops, solution - 0.2 % - active: brimonidine tartrate 2 mg/ml   excipient: benzalkonium chloride citric acid monohydrate hydrochloric acid polyvinyl alcohol purified water sodium chloride sodium citrate dihydrate sodium hydroxide - alphagan® eye drops are effective for lowering intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - brimonidine tartrate - ophthalmic solution - brimonidine tartrate 0.15 %w/v - brimonidine - brimonidine - alphagan is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - brimonidine tartrate 1.5 mg in 1 ml - alphagan ® p (brimonidine tartrate ophthalmic solution) 0.1% or 0.15% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. alphagan ® p is contraindicated in neonates and infants (under the age of 2 years). alphagan ® p is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past. pregnancy category b: teratogenicity studies have been performed in animals. brimonidine tartrate was not teratogenic when given orally during gestation days 6 through 15 in rats and days 6 through 18 in rabbits. the highest doses of brimonidine tartrate in rats (2.5 mg/kg/day) and rabbits (5.0 mg/kg/day) achieved auc exposure values 360- and 20-fold higher, or 260- and 15-fold higher, respectively, than similar values estimated in humans treated with alphagan ® p 0.1% or 0.15%, 1 drop in both eyes three times daily. there are no adequate and well-

United States - English - NLM (National Library of Medicine)

allergan, inc. - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - brimonidine tartrate 1 mg in 1 ml - alphagan ® p (brimonidine tartrate ophthalmic solution) 0.1% or 0.15% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. alphagan ® p is contraindicated in neonates and infants (under the age of 2 years).  alphagan ® p is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past. pregnancy category b: teratogenicity studies have been performed in animals. brimonidine tartrate was not teratogenic when given orally during gestation days 6 through 15 in rats and days 6 through 18 in rabbits. the highest doses of brimonidine tartrate in rats (2.5 mg/kg/day) and rabbits (5.0 mg/kg/day) achieved auc exposure values 360- and 20-fold higher, or 260- and 15-fold higher, respectively, than similar values estimated in humans treated with alphagan ® p 0.1% or 0.15%, 1 drop in both eyes three times daily. there are no adequate and

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - brimonidine tartrate, quantity: 2 mg/ml - eye drops, solution - excipient ingredients: sodium hydroxide; purified water; sodium chloride; polyvinyl alcohol; citric acid; benzalkonium chloride; hydrochloric acid; sodium citrate dihydrate - indications: alphagan eye drops are effective as monotherapy for lowering intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension in whom (beta symbol)-blockers are not tolerated or are contraindicated. indications as at 7 december 1999: alphagan eye drops are effective in lowering elevated intraocular pressure in patients with chronic open angle glaucoma or ocular hypertension. alphagan eye drops can be used in the treatment of glaucoma either as monotherapy or in combination with topical beta-blockers.

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - brimonidine tartrate 1.5 mg/ml;   - eye drops, solution - 1.5 mg/ml - active: brimonidine tartrate 1.5 mg/ml   excipient: boric acid calcium chloride dihydrate carmellose sodium hydrochloric acid magnesium chloride hexahydrate potassium chloride purified water sodium borate pentahydrate sodium chloride sodium chlorite as purite sodium hydroxide - alphagan® p 1.5 eye drops are effective for lowering intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

allergan australia pty ltd - brimonidine tartrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

allergan australia pty ltd - brimonidine tartrate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

allergan malaysia sdn bhd - brimonidine tartrate -